Comparative Risk of Complications Following Intestinal Surgery After Infliximab, Vedolizumab, or Ustekinumab Treatment: Systematic Review & Meta-Analysis
Pharmaceuticals · 29.09.2025 · 18 (10) · 1466
DOI: 10.3390/ph18101466 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 29.09.2025. Verfasst von Alexandra-Eleftheria Menni und 5 weiteren Autor:innen. Beteiligte Einrichtung: 1st Propaedeutic Department of Surgery, AHEPA University Hospital, 54636 Thessaloniki, Greece. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Treatment of inflammatory bowel diseases with biological therapies has significantly increased, with ever increasing numbers of patients receiving such treatment at the time of surgery. This study evaluates the perioperative safety of three commonly used biologics—Infliximab, Vedolizumab, or Ustekinumab—in patients undergoing intestinal surgery for IBDs. Materials and Methods: In this systematic review a comprehensive search was conducted in Scopus, Medline and PubMed up to January 2025 by two independent reviewers, and a total of 34 articles (retrospective studies in the majority of them) reporting total surgical complications of patients treated with these three agents, in comparison to a control group, were included. Relative risks were aggregated using the Mantel-Haenszel method, and the I2 statistic was used to assess between-study heterogeneity. Subgroup analyses were conducted for particular complications, and direct comparisons among the biological agents were made.
Results
In the primary analysis, INFL was not linked to a statistically significant rise in overall postoperative complications when compared to controls (RR = 1.13, 95% CI: 0.90–1.42, p = 0.31). VDLZ exhibited a non-significant inclination towards increased complications (RR = 1.26, 95% CI: 0.94–1.67, p = 0.12), although it was linked to a notably higher risk of postoperative ileus compared to INFL (RR = 2.29, 95% CI: 1.59–3.29, p < 0.00001). USTK also did not show significant differences from controls overall (RR = 0.55, 95% CI: 0.20–1.57, p = 0.26), though it was associated with a considerably lower risk of SSIs (RR = 0.35, 95% CI: 0.17–0.73, p = 0.005). There were no significant distinctions between the biological agents regarding SSIs or anastomotic leakage, although many comparisons faced challenges due to high heterogeneity and low event rates.
Conclusions
USTK demonstrated the most favorable safety profile, while VDLZ was associated with higher rates of ileus and inflammatory complications. However, prospective studies are warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 1st Propaedeutic Department of Surgery, AHEPA University Hospital, 54636 Thessaloniki, Greece.
- Pathology Department, Medical School, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
- General Surgery Department, Metropolitan Hospital, 18547 Athens, Greece.
ORCID-Profile: Alexandra-Eleftheria Menni, George Petrakis
Zitieren
APA
Menni, A. E., Tzikos, G., Petrakis, G., Goulas, P., Karathanasis, P. V., & Apostolidis, S. (2025). Comparative Risk of Complications Following Intestinal Surgery After Infliximab, Vedolizumab, or Ustekinumab Treatment: Systematic Review & Meta-Analysis. Pharmaceuticals, 18(10), 1466. https://doi.org/10.3390/ph18101466
Vancouver
Menni AE, Tzikos G, Petrakis G, Goulas P, Karathanasis PV, Apostolidis S. Comparative Risk of Complications Following Intestinal Surgery After Infliximab, Vedolizumab, or Ustekinumab Treatment: Systematic Review & Meta-Analysis. Pharmaceuticals. 2025;18(10):1466. doi:10.3390/ph18101466
BibTeX
@article{Menni2025,
author = {Menni, Alexandra-Eleftheria and Tzikos, Georgios and Petrakis, George and Goulas, Patroklos and Karathanasis, Panagiotis V and Apostolidis, Stylianos},
title = {Comparative Risk of Complications Following Intestinal Surgery After Infliximab, Vedolizumab, or Ustekinumab Treatment: Systematic Review & Meta-Analysis},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {10},
pages = {1466},
doi = {10.3390/ph18101466}
}
EUVIMED